Skip to main content

Breast Cancer

From the Literature, Breast Cancer

Trastuzumab Deruxtecan Shows Durable Antitumor Activity in HER2-Positive Metastatic Breast Cancer

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

Commentary by Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

Meeting Highlights

Breast Cancer, ESMO Highlights

Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care

Breast Cancer, Multiple Myeloma, Pediatric Cancer, FDA Oncology Update

Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News

Breast Cancer, FDA Updates, Drug Profiles/Updates

Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

Breast Cancer, FDA Oncology Update

FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer

Yvette Florio Lane

Breast Cancer, FDA Oncology Update

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Yvette Florio Lane

Breast Cancer, FDA Oncology Update

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

Yvette Florio Lane

Breast Cancer

5 mg Tamoxifen as Effective as 20 mg Daily in Early Localized Breast Cancer

Breast Cancer

Less Is More: Six Months of Traxtuzumab Equivalent to 12 Months in HER2-Positive Breast Cancer

Breast Cancer

First-in-Class Antibody-Drug Conjugate Effective in HER2-Negative Metastatic Breast Cancer

6
7
8
9
10
11

Page 9 of 11
Results 81 - 90 of 101